The success of the bivalent Nb against von Willebrand factor, caplacizumab, which is used to treat the rare genetic disease, immune thrombotic thrombocytopenic purpura51, 52 sets a good precedent for the use of Nbs to treat platelet‐related disorders. Here, VWF is linked to hereditary disease.